GEORGE WASHINGTON UNIVERSITY

GenomOncology appoints Dr. Jonathan "Jack" Lord, M.D., to its Board of Directors. Dr. Lord, a healthcare innovation leader, brings extensive experience in clinical practice, healthcare administration, and advanced analytics. His appointment aligns with GenomOncology's mission to advance precision medicine in oncology.

Artificial sweetener use linked to lower diet quality, with increased intake associated with less fruit/vegetable consumption and more processed foods, per a study in the American Journal of Clinical Nutrition.

The FDA approved Nemluvio® (nemolizumab) for treating moderate-to-severe atopic dermatitis in patients 12+ years old, in combination with topical corticosteroids and/or calcineurin inhibitors. Nemluvio, targeting IL-31 receptor alpha, is the first monoclonal antibody to inhibit IL-31 signaling, addressing itch and inflammation. This approval follows its earlier approval for prurigo nodularis in August 2024.

Republicans plan to use the Congressional Review Act (CRA) to swiftly overturn Biden-era regulations, especially 'midnight regulations.' The CRA allows Congress to review and nullify new federal regulations within 60 legislative days, bypassing the filibuster. Biden-era environmental rules, immigration policies, and diversity initiatives are likely targets for repeal.

Maneesh R. Jain, MD, discusses a case of HER2-positive prostate cancer treated with trastuzumab deruxtecan-nxki (Enhertu), highlighting the patient's dramatic response and the importance of HER2 expression testing in prostate cancer. A clinical trial (CaRPET) is planned to explore this treatment further.

Dr. Maneesh Jain and team used trastuzumab deruxtecan (T-DXd) on a 60-year-old Veteran with stage four metastatic prostate cancer, achieving a 57% tumor reduction. This case marks the first use of T-DXd for prostate cancer, published in Annals of Internal Medicine, suggesting potential for targeted therapies in advanced cases.